{"entity":{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","aka":[],"tldr":"A Chinese bispecific that beat Keytruda head-to-head on progression-free survival in lung cancer, the first drug ever to do so.","summary":"HARMONi-2 (China): PFS 11.1 vs 5.8 months versus pembrolizumab in PD-L1+ first-line NSCLC. Approved in China (2024) for EGFR-mutant NSCLC after TKI (HARMONi-A) and first-line PD-L1+ NSCLC. Summit Therapeutics holds Western rights; HARMONi (global, EGFR-mutant post-TKI) met PFS but OS was not statistically significant in 2025; HARMONi-3 (squamous and non-squamous first-line) ongoing. Spawned a wave of PD-(L)1×VEGF bispecifics (Pfizer/3SBio, BMS/BioNTech, Merck/LaNova).","status":"approved","asOf":"2026-09-04","links":[{"label":"ClinicalTrials.gov: trials of Ivonescimab","url":"https://clinicaltrials.gov/search?intr=AK112"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","tnbc","pdl1-high-nsclc"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor"],"targets":["pd1","vegf"],"drugs":[],"companies":["akeso","summit-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07010263","nct06767527","nct06928389","nct06396065","nct06767514","nct05840016","nct06686030","nct05846867","nct06646055","nct07397338","nct07208773","nct05904379","nct07052253","nct07245446","nct06560112","nct07623356","nct05382442","nct05247684","nct07669779","nct06530251","nct07815665","nct06953999","nct06877650"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"AK112, SMT112","modality":"Bispecific antibody (PD-1×VEGF)","mechanism":"Tetravalent PD-1×VEGF-A bispecific with cooperative binding: VEGF binding increases PD-1 affinity, concentrating activity in tumour.","approvals":[{"region":"China","year":2024,"indication":"EGFR-mutant NSCLC after TKI (with chemotherapy); first-line PD-L1+ NSCLC"}],"mechanismSteps":["Tetravalent antibody binds VEGF-A in the tumour microenvironment","VEGF binding increases the antibody's affinity for PD-1 (cooperative binding), concentrating it in tumour","PD-1 blockade releases T cells; VEGF neutralisation normalises vessels and reduces immunosuppressive myeloid cells","Improved T-cell infiltration and killing"],"dosing":{"route":"IV infusion","schedule":"20 mg/kg every 3 weeks (China label; HARMONi-2)","modifications":"Standard immune-mediated event algorithm plus VEGF-class precautions (bleeding, hypertension, proteinuria)","monitoring":"Blood pressure, urine protein, thyroid, LFTs","source":"https://www.akesobio.com"},"toxicity":[{"event":"Proteinuria"},{"event":"Hypertension"},{"event":"Anaemia"},{"event":"AST increased"},{"event":"Hypothyroidism"},{"event":"Haemorrhage (low grade)"}],"access":[{"country":"CN","reimbursement":"NMPA approved 2024; NRDL inclusion 2025","asOf":"2026-09-06"},{"country":"US","reimbursement":"Investigational; BLA under review (PDUFA 14 November 2026)","asOf":"2026-09-06"}],"regulatoryEvents":[{"date":"2024-05-24","type":"approval","region":"China","note":"EGFR-mutant NSCLC after TKI, with chemotherapy (HARMONi-A)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2025-04","type":"approval","region":"China","note":"First-line PD-L1+ NSCLC (HARMONi-2)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2026-01","type":"filing","region":"US","note":"BLA submitted by Summit for EGFR-mutant NSCLC after TKI (HARMONi)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2026-11-14","type":"pdufa","region":"US","note":"PDUFA target date","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}]},"route":"/drugs/ivonescimab/","neighbours":{"cancer":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"},{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/"}],"trial":[{"id":"nct06936644","kind":"trial","name":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","route":"/trials/nct06936644/"},{"id":"nct05846867","kind":"trial","name":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","route":"/trials/nct05846867/"},{"id":"nct07052253","kind":"trial","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","route":"/trials/nct07052253/"},{"id":"nct07669779","kind":"trial","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07669779/"},{"id":"nct06953999","kind":"trial","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","route":"/trials/nct06953999/"},{"id":"nct07010263","kind":"trial","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","route":"/trials/nct07010263/"},{"id":"nct07357220","kind":"trial","name":"A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases","route":"/trials/nct07357220/"},{"id":"nct06530251","kind":"trial","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","route":"/trials/nct06530251/"},{"id":"nct05382442","kind":"trial","name":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","route":"/trials/nct05382442/"},{"id":"nct07623356","kind":"trial","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07623356/"},{"id":"nct07412262","kind":"trial","name":"A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig","route":"/trials/nct07412262/"},{"id":"nct07535437","kind":"trial","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","route":"/trials/nct07535437/"},{"id":"nct07815665","kind":"trial","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","route":"/trials/nct07815665/"},{"id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","route":"/trials/nct07245446/"},{"id":"nct07535463","kind":"trial","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","route":"/trials/nct07535463/"},{"id":"nct07602855","kind":"trial","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","route":"/trials/nct07602855/"},{"id":"nct07208773","kind":"trial","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","route":"/trials/nct07208773/"},{"id":"nct06944106","kind":"trial","name":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","route":"/trials/nct06944106/"},{"id":"nct06844422","kind":"trial","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","route":"/trials/nct06844422/"},{"id":"nct05904379","kind":"trial","name":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","route":"/trials/nct05904379/"},{"id":"nct06646055","kind":"trial","name":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct06646055/"},{"id":"nct07767994","kind":"trial","name":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer","route":"/trials/nct07767994/"},{"id":"nct05840016","kind":"trial","name":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05840016/"},{"id":"nct07158840","kind":"trial","name":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor","route":"/trials/nct07158840/"},{"id":"nct05247684","kind":"trial","name":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","route":"/trials/nct05247684/"},{"id":"nct06767527","kind":"trial","name":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","route":"/trials/nct06767527/"},{"id":"nct07021950","kind":"trial","name":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","route":"/trials/nct07021950/"},{"id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","route":"/trials/nct07590531/"},{"id":"nct06560112","kind":"trial","name":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","route":"/trials/nct06560112/"},{"id":"nct06767514","kind":"trial","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","route":"/trials/nct06767514/"},{"id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","route":"/trials/nct06686030/"},{"id":"nct06951646","kind":"trial","name":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","route":"/trials/nct06951646/"},{"id":"ea2197-ivonescimab","kind":"trial","name":"EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer","route":"/trials/ea2197-ivonescimab/"},{"id":"nct06877650","kind":"trial","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","route":"/trials/nct06877650/"},{"id":"harmoni-2","kind":"trial","name":"HARMONi-2","route":"/trials/harmoni-2/"},{"id":"harmoni-3","kind":"trial","name":"HARMONi-3","route":"/trials/harmoni-3/"},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/"},{"id":"nct07405190","kind":"trial","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","route":"/trials/nct07405190/"},{"id":"nct06928389","kind":"trial","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06928389/"},{"id":"nct06993025","kind":"trial","name":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","route":"/trials/nct06993025/"},{"id":"nct06848842","kind":"trial","name":"Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases","route":"/trials/nct06848842/"},{"id":"nct06991491","kind":"trial","name":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","route":"/trials/nct06991491/"},{"id":"nct06491472","kind":"trial","name":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","route":"/trials/nct06491472/"},{"id":"nct07743632","kind":"trial","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","route":"/trials/nct07743632/"},{"id":"nct06790212","kind":"trial","name":"Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer","route":"/trials/nct06790212/"},{"id":"nct06718543","kind":"trial","name":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","route":"/trials/nct06718543/"},{"id":"nct06977542","kind":"trial","name":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","route":"/trials/nct06977542/"},{"id":"nct07819591","kind":"trial","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","route":"/trials/nct07819591/"},{"id":"nct06959550","kind":"trial","name":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","route":"/trials/nct06959550/"},{"id":"nct07234877","kind":"trial","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","route":"/trials/nct07234877/"},{"id":"nct07017673","kind":"trial","name":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","route":"/trials/nct07017673/"},{"id":"nct06396065","kind":"trial","name":"Phase III Study of AK112 for NSCLC Patients","route":"/trials/nct06396065/"},{"id":"nct07103447","kind":"trial","name":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","route":"/trials/nct07103447/"},{"id":"nct07162714","kind":"trial","name":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","route":"/trials/nct07162714/"},{"id":"sevilla","kind":"trial","name":"SEVILLA","route":"/trials/sevilla/"},{"id":"nct06802666","kind":"trial","name":"Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct06802666/"},{"id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/"},{"id":"nct07359456","kind":"trial","name":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","route":"/trials/nct07359456/"}],"pathway":[{"id":"immune-desert-exclusion","kind":"pathway","name":"Cold tumours: immune deserts and exclusion","route":"/pathways/immune-desert-exclusion/"},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"},{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/"},{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"},{"id":"vegf-angiogenesis","kind":"pathway","name":"VEGF angiogenesis","route":"/pathways/vegf-angiogenesis/"}],"pairing":[{"id":"io-plus-vegf","kind":"pairing","name":"PD-1 blockade + VEGF inhibition","route":"/pairings/io-plus-vegf/"}],"roadmap":[{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/"}],"person":[{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/"},{"id":"xia-michelle","kind":"person","name":"Michelle Xia (Xia Yu)","route":"/people/xia-michelle/"},{"id":"qing-zhou","kind":"person","name":"Qing Zhou","route":"/people/qing-zhou/"},{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/"}],"paper":[{"id":"paper-harmoni-2-lancet-2025","kind":"paper","name":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","route":"/key-papers/paper-harmoni-2-lancet-2025/"}],"term":[{"id":"angiogenesis","kind":"term","name":"Angiogenesis","route":"/terms/angiogenesis/"}],"institution":[{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/"},{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/"},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/"}]}}